Trial Profile
Safety and immunogenicity study of nivolumab with or without GS-4774 in patients with HBeAg negative chronic hepatitis B infection
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Nov 2017
Price :
$35
*
At a glance
- Drugs GS 4774 (Primary) ; Nivolumab (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 24 Oct 2017 Results assessing immunological aseessment presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases.
- 08 Jul 2017 New trial record